Skip to content

Wrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis

The Role of Wrist Nerve Block as a Therapeutic Modality in Patients With Rheumatoid Arthritis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07814989
Acronym
RA: rheumatoid
Enrollment
180
Registered
2026-09-11
Start date
2026-08-15
Completion date
2027-07-01
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhematoid Arthritis

Keywords

Rheumatoid Arthritis, Nerve block, Wrist injection

Brief summary

Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues.\[1\]

Interventions

Wrist nerve block by injection is a diagnostic or therapeutic procedure used to treat chronic wrist pain, typically arising from arthritis or instability, by interrupting sensory nerve signals (mainly PIN/AIN nerves) with an anesthetic or neurolytic agent. This less-invasive approach provides pain relief, often serving as a predictor for success before permanent surgical denervation.\[4\]

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. RA patients fulfilled the 2010 American College of Rheumatoid Arthritis classification criteria.\[8\] 2. Oligoarticular RA patients including wrist joint. 3. Age above 18 years old. 4. Patient cooperative and can answer questions.

Exclusion criteria

1. Other rheumatologic or collagen diseases. 2. Age below 18 years. 3. Patients who underwent concomitant procedures to address underlying pathology such as radial styloidectomy, ulna shortening, fracture fixation, arthroplasty, arthrodesis, and ligament reconstructions. 4. Patients who suffered from hand deformities or limitation. 5. Uncooperative patients.

Design outcomes

Primary

MeasureTime frameDescription
Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16Baseline to Week 16Change in wrist pain severity measured using the Visual Analogue Scale (VAS) from baseline to Week 16 Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Wrist pain severity will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate greater pain. The change in VAS score from baseline to Week 16 will be assessed.
Assessment of wrist pain improvement16 weeks• Change in wrist pain severity measured by the Visual Analogue Scale (VAS) from baseline to Week 16

Countries

Egypt

Contacts

CONTACTYoussra Ali Resident
youssralam3ie@gmail.com00201122040682
CONTACTAhmed mahrous elsamman
00201122040682

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026